ClinicalTrials.gg
CompletedNCT02841709Updated Apr 24, 2020Results posted

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

A Phase 2 interventional study of ACT-541468 and Placebo in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 10 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
15th of 16
58 · median 165
Started
2016
with 1 other
Phase 2
4 of 16
1 open now
Registered
3rd of 16
by date
Lead sponsor
8 of 16
Idorsia Pharmaceuticals Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 15th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 3rd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.

Read the detailed description

The study consists of 3 phases: a screening phase, a double-blind treatment phase consisting of 5 periods, and a safety follow-up phase. Safety is monitored throughout the study.

03

Conditions studied

  • Insomnia Disorder

Keywords

  • insomnia
  • elderly
  • Polysomnography
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure.
  • Male or female aged ≥ 65 years.
  • (BMI): 18.5 ≤ BMI (kg/m2 ) \< 32.0
  • Insomnia disorder according to criteria.
  • Self-reported history of insufficient sleep quantity.
  • Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography.
  • Insomnia Severity Index score ≥ 15.

Exclusion criteria

Exclusion Criteria:

  • Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.
  • Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week.
  • Caffeine consumption ≥ 600 mg per day.
  • Shift work within 2 weeks prior to the screening visit, or planned shift work during study.
  • Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel ≥ 3 time zones during study.
  • Hematology or biochemistry test results deviating from the normal range to a extent as per judgment of the Investigator.
  • and/or ALT > 2 × and/or > 1.5 × ULN (except known history of Gilbert's syndrome);
  • Severe renal impairment (known or defined as estimated \< 30 mL/min);
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.

    Drug: ACT-541468 · Drug: Placebo

  • Experimental
    Sequence 2

    Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.

    Drug: ACT-541468 · Drug: Placebo

  • Experimental
    Sequence 3

    Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.

    Drug: ACT-541468 · Drug: Placebo

  • Experimental
    Sequence 4

    Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.

    Drug: ACT-541468 · Drug: Placebo

  • Experimental
    Sequence 5

    Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.

    Drug: ACT-541468 · Drug: Placebo

Interventions

  • Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg

  • DrugPlacebo

    Capsules for oral administration matching the ACT-541468 capsules

06

What researchers measure

Primary outcomes

  1. Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2

    WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)

    Time frame: Baseline to Day 1 and Day 2 of each treatment period

Secondary outcomes

  1. Change in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2

    LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG

    Time frame: Baseline to Day 1 and Day 2 of each treatment period

07

Results

Posted Apr 24, 2020

Participant flow

Conducted at 10 centers in 2 countries (USA and Germany)

1st Intervention
Participant flow — 1st Intervention
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
Washout Period 1
Participant flow — Washout Period 1
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
2nd Intervention
Participant flow — 2nd Intervention
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
Washout Period 2
Participant flow — Washout Period 2
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
3rd Intervention
Participant flow — 3rd Intervention
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
Washout Period 3
Participant flow — Washout Period 3
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
4th Intervention
Participant flow — 4th Intervention
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
Washout Period 4
Participant flow — Washout Period 4
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed1211121211
Not completed00000
5th Intervention
Participant flow — 5th Intervention
MilestoneSequence 1 (D4, D2, D3, D1 and P)Sequence 2 (D2, P, D4, D3 and D1)Sequence 3 (D3, D1, D2, P and D4)Sequence 4 (P, D4, D1, D2 and D3)Sequence 5 (D1, D3, P, D4 and D2)
Started1211121211
Completed101112129
Not completed20002
Withdrew: Adverse event20002

Outcome measures

PrimaryChange in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2

WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)

Time frame:
Baseline to Day 1 and Day 2 of each treatment period
Reported as:
Least squares mean · minutes
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2
minutesACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgPlacebo
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2-18.9 ± 4.44-32.0 ± 4.50-45.1 ± 4.47-61.4 ± 4.44-13.6 ± 4.50
Statistical analysis
  • ACT-541468 5 mg vs ACT-541468 10 mg vs ACT-541468 25 mg vs ACT-541468 50 mg vs Placebo · Multiple Comparison Procedure-Model · p = <0.001
  • ACT-541468 5 mg vs Placebo · Linear mixed effects model · p = 0.258 · Ls mean difference: -5.4 · 95% CI -14.7 to 4.0Parameter Dispersion Type: Standard Error of the LS Mean
  • ACT-541468 10 mg vs Placebo · Linear mixed effects model · p = <0.001 · Ls mean difference: -18.4 · 95% CI -27.8 to -9.0Parameter Dispersion Type: Standard Error of the LS Mean
  • ACT-541468 25 mg vs Placebo · Linear mixed effects model · p = <0.001 · Ls mean difference: -31.5 · 95% CI -40.9 to -22.2
  • ACT-541468 50 mg vs Placebo · Linear mixed effects model · p = <0.001 · Ls mean difference: -47.8 · 95% CI -57.2 to -38.5
SecondaryChange in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2

LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG

Time frame:
Baseline to Day 1 and Day 2 of each treatment period
Reported as:
Mean · Minutes
Change in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2
MinutesACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mgPlacebo
Change in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2-37.92 ± 48.76-44.61 ± 41.28-44.81 ± 41.56-44.88 ± 44.22-33.88 ± 41.74

Adverse events

Collected over Start of screening until the end of the safety follow-up period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single-blind Placebo (Run-in Period)0/58 (0%)0/58 (0%)7/58 (12.1%)
Placebo0/54 (0%)0/54 (0%)11/54 (20.4%)
ACT-541468 5 mg0/56 (0%)0/56 (0%)14/56 (25%)
ACT-541468 10 mg0/54 (0%)0/54 (0%)12/54 (22.2%)
ACT-541468 25 mg0/55 (0%)0/55 (0%)10/55 (18.2%)
ACT-541468 50 mg0/56 (0%)0/56 (0%)16/56 (28.6%)
Most frequent other events
Showing 10 of 58
Most frequent other events
EventSingle-blind Placebo (Run-in Period)PlaceboACT-541468 5 mgACT-541468 10 mgACT-541468 25 mgACT-541468 50 mg
FatigueGeneral disorders0/582/540/561/540/554/56
Back painMusculoskeletal and connective tissue disorders0/582/540/560/541/550/56
Gait disturbanceGeneral disorders1/580/542/561/541/551/56
NasopharyngitisInfections and infestations0/581/541/561/540/552/56
DizzinessNervous system disorders0/580/542/561/540/550/56
HeadacheNervous system disorders2/581/542/560/541/551/56
Bundle branch block leftCardiac disorders0/581/540/560/540/550/56
Cerumen impactionEar and labyrinth disorders0/581/540/560/540/550/56
Abdominal discomfortGastrointestinal disorders0/581/540/560/540/550/56
Defaecation urgencyGastrointestinal disorders0/580/541/561/541/550/56

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years57
>=65 years1
Age, Continuous
Age, Continuous(years)All Study Participants
Median69 (65 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female39
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino1
Not Hispanic or Latino57
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White54
More than one race0
Unknown or Not Reported0
Insomnia Severity Index
Insomnia Severity Index(units on a scale)All Study Participants
Mean20 (15 to 28)
08

Study locations

10 sites
  • Investigator Site
    Brandon, Florida 33511, United States
  • Investigator Site
    Chicago, Illinois 60634, United States
  • Investigator Site
    Las Vegas, Nevada 89104, United States
  • Investigator Site
    New York, New York 10019, United States
  • Investigator Site
    Cincinnati, Ohio 45255, United States
  • Investigator Site
    Berlin, 10115, Germany
  • Investigator Site
    Berlin, 10117, Germany
  • Investigator Site
    Hamburg, 20253, Germany
  • Investigator Site
    Hannover, 30159, Germany
  • Investigator Site
    Schwerin, 19053, Germany
09

References and documents

Publications

  • Zammit G, Dauvilliers Y, Pain S, Sebok Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020 May 26;94(21):e2222-e2232. doi: 10.1212/WNL.0000000000009475. Epub 2020 Apr 27. PubMed 32341187 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in May 2017, 6 months.

Results were first posted in Apr 2020, 2 years 10 months after primary completion. A results delay was requested in Apr 2018.

Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Jul 22, 2016
StartActual
Nov 28, 2016
Primary completionActual
May 31, 2017
CompletionActual
Jun 29, 2017
Results delay requested
Apr 26, 2018
Results first posted
Apr 24, 2020
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02841709
Responsible party
Sponsor
First posted
Jul 22, 2016
Start date
Nov 28, 2016
Primary completion
May 31, 2017
Completion
Jun 29, 2017
Results posted
Apr 24, 2020
Last update
Apr 24, 2020

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion